Open AccessMetabolic syndrome in rheumatoid arthritis patients: Relationship among its clinical components
Author(s) -
GarcíaChagollán Mariel,
HernándezMartínez Susana Elizabeth,
RojasRomero Alma Elizabeth,
MuñozValle José Francisco,
SigalaArellano Ramón,
CerpaCruz Sergio,
MoralesNúñez José Javier,
LomelíNieto José Alvaro,
Macedo Ojeda Gabriela,
HernándezBello Jorge
Publication year - 2021
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.23666
Subject(s) - rheumatoid arthritis , metabolic syndrome , medicine , arthritis , obesity
Background Metabolic syndrome (MetS) prevalence in rheumatoid arthritis (RA) patients is known to vary considerably across the world. This study aimed to determine the prevalence of MetS in RA patients from western Mexico and to analyze the interrelation of the MetS components with the clinical variables of RA. Methods This case‐control study included 216 RA patients and 260 control subjects (CS). MetS prevalence was determined according to the NCEP/ATP III and the Latin American Consensus of the Latin American Diabetes Association (ALAD) criteria. Results MetS was observed in 30.6% RA patients and 33.3% of controls ( p > 0.05) according to NCEP/ATP III and 28.7% in RA patients and 31.1% for controls using ALAD criteria. Total cholesterol, LDL‐C, and Castelli's I‐II indexes were lower in RA ( p < 0.001) than in CS. The RA patients with MetS had more swollen joints than those without MetS ( p = 0.018). In RA patients with MetS, DAS‐28 score correlated with smoking index (rho = 0.4601, p = 0.0004) and VLDL‐C (rho = 0.3108, p = 0.0056); similarly, rheumatoid factor (RF) correlated with age (rho = 0.2031, p = 0.0027), smoking index (rho = 0.3404, p < 0.0001), triglycerides (rho = 0.1958, p = 0.0039), and VLDL‐C (rho = 0.1761, p = 0.0162). Conclusions The MetS prevalence in RA patients from western Mexico is not higher than controls; however, in RA patients with MetS, some inflammatory markers are associated with MetS components; thus, the control of MetS in RA could be beneficial to regulate disease activity.